Wegovy vs Mounjaro: Cost and Access Head-to-Head Comparison

List Price Comparison: What Each Drug Actually Costs

Both medications sit in a similar price band at wholesale acquisition cost (WAC), though exact figures shift with dose escalation and periodic manufacturer adjustments. Wegovy's WAC for the 2.4 mg maintenance pen runs approximately $1,349/month. Mounjaro's WAC starts around $1,023 for the 5 mg dose and rises with higher titration levels 1.

Dose Escalation and Cumulative Cost

Neither drug begins at its maintenance dose. Wegovy requires a 16-week titration from 0.25 mg to 2.4 mg across four dose steps. Mounjaro starts at 2.5 mg with increases every four weeks. The total cost of the titration period (months 1 through 4 or 5) is roughly equivalent between the two, assuming identical per-pen pricing structures. Patients who require slower titration due to GI side effects may spend additional months at sub-therapeutic doses, increasing cumulative spend before reaching full efficacy.

Net Price vs List Price

Pharmacy benefit managers (PBMs) negotiate rebates that reduce the net cost to insurers, but these discounts do not always reach the patient at the pharmacy counter. The actual rebate percentages for Wegovy and Mounjaro are proprietary. Industry estimates suggest net prices after rebates fall 40-60% below WAC for preferred formulary agents 2. Which drug commands a larger rebate depends on the specific PBM contract and volume tier.

Insurance Coverage and Formulary Placement

The single largest determinant of out-of-pocket cost is whether your insurance plan covers the drug at all. This is not a simple yes-or-no question. Coverage depends on indicated use, formulary tier, step therapy requirements, and quantity limits.

Commercial Insurance

Among large employer-sponsored plans, coverage for anti-obesity medications has expanded but remains inconsistent. A 2023 KFF employer survey found that roughly 44% of large firms covered at least one GLP-1 receptor agonist for weight management. Wegovy's explicit FDA obesity approval (June 2021) gives it a documentation advantage during prior authorization for BMI-based prescribing. Mounjaro's FDA approval is for type 2 diabetes; its obesity-specific sibling, Zepbound (tirzepatide), received approval in November 2023 and occupies its own formulary slot on most plans.

Medicare and Medicaid

Medicare Part D historically excluded coverage for weight-loss medications under the statutory "anti-obesity agent" exclusion. The Treat and Reduce Obesity Act, if enacted, would change this. As of mid-2026, most Medicare Part D plans do not cover Wegovy for obesity but may cover it under its cardiovascular risk-reduction indication following the SELECT trial results 3. Mounjaro is covered under Part D for type 2 diabetes. Medicaid coverage varies by state; fewer than half of state Medicaid programs cover anti-obesity medications without restrictions.

Prior Authorization Requirements

Both drugs typically require prior authorization. Common criteria include documented BMI of 30+ (or 27+ with a comorbidity), failure of lifestyle interventions for 3-6 months, and sometimes step therapy showing inadequate response to older agents like phentermine or orlistat. Denial rates run 20-30% on initial submission for anti-obesity indications, according to pharmacy adjudication data from 2024.

Manufacturer Savings Programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro/Zepbound) operate copay savings cards for commercially insured patients. These programs can reduce monthly costs to $0-$25 for eligible patients, but the eligibility criteria and caps differ.

Wegovy Savings Card

Novo Nordisk's savings offer covers patients with commercial insurance whose plan covers Wegovy. The card reduces the copay to as low as $0 for up to 13 fills. Patients without insurance coverage for Wegovy are not eligible for the standard savings card but may qualify for Novo Nordisk's patient assistance program (PAP) if household income falls below 400% of the federal poverty level.

Mounjaro/Zepbound Savings Card

Eli Lilly's savings program has undergone multiple revisions. The current iteration for Zepbound (the obesity-indicated brand) offers eligible commercially insured patients a copay as low as $25/month. For Mounjaro prescribed for T2D, a separate savings card applies. Patients using government insurance (Medicare, Medicaid, TRICARE) are excluded from both cards.

Head-to-Head Savings Comparison

For a commercially insured patient whose plan covers either drug, the net monthly out-of-pocket is comparable: $0-$25 with active manufacturer copay support. The difference emerges when insurance does not cover the medication. Lilly has periodically offered a cash-pay program for Zepbound at $399-$549/month for patients willing to pay out-of-pocket without insurance, while Novo Nordisk's cash-pay options for Wegovy have been more limited and typically closer to full list price.

Clinical Efficacy Context for the Cost Discussion

Cost cannot be evaluated without referencing what each dollar buys in clinical outcomes. No direct head-to-head randomized trial comparing semaglutide 2.4 mg (Wegovy) to tirzepatide at anti-obesity doses has been published as of this writing. Cross-trial comparisons offer indirect evidence.

STEP-1 Results for Wegovy

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg achieved 14.9% mean body-weight loss at 68 weeks compared to 2.4% with placebo 3. The trial enrolled adults with BMI of 30+ (or 27+ with at least one weight-related comorbidity) without diabetes. Over one-third of participants lost 20% or more of their body weight.

SURPASS-2 Results for Mounjaro

SURPASS-2 (N=1,879) compared tirzepatide (5, 10, and 15 mg) against semaglutide 1 mg in adults with type 2 diabetes 2. At 40 weeks, tirzepatide 15 mg produced 12.4% body-weight reduction vs 6.2% for semaglutide 1 mg. The semaglutide comparator was 1 mg (Ozempic dose), not the 2.4 mg Wegovy dose, which limits direct extrapolation.

SURMOUNT Trials

The SURMOUNT-1 trial tested tirzepatide specifically for obesity (not diabetes) and reported 22.5% mean weight loss at 72 weeks with the 15 mg dose. This positions tirzepatide's anti-obesity efficacy as numerically higher than semaglutide 2.4 mg in STEP-1, though the trials used different populations, durations, and endpoints.

Cost-Effectiveness Analyses

Published cost-effectiveness models yield different conclusions depending on the perspective (payer vs societal), time horizon, and assumed drug discontinuation rates.

ICER Assessment

The Institute for Clinical and Economic Review (ICER) assessed semaglutide 2.4 mg in 2022 and concluded that the drug would meet conventional cost-effectiveness thresholds ($100,000-$150,000/QALY) only at a net price roughly 40% below list. ICER's 2023 assessment of tirzepatide for obesity reached a similar conclusion: clinically superior weight loss, but cost-effectiveness depends heavily on negotiated price.

Real-World Cost Per Percent Weight Lost

A rough back-of-envelope calculation: at list price over 68 weeks, Wegovy costs approximately $21,000 in total medication spend for an average 14.9% weight loss, yielding about $1,400 per percentage point of weight lost. For tirzepatide at the 15 mg SURMOUNT-1 result (22.5% at 72 weeks), total spend is approximately $18,000-$20,000 for $800-$900 per percentage point. These figures assume no insurance, no savings card, and continuous supply at list price.

Access Barriers Beyond Price

Cost is only one dimension of access. Supply chain reliability, prescriber availability, and geographic factors all shape whether a patient can actually obtain either medication.

Supply Chain Constraints

Wegovy experienced severe supply shortages from late 2022 through mid-2024 as demand outstripped Novo Nordisk's manufacturing capacity. By Q3 2024, all dose strengths returned to adequate supply per FDA shortage tracking. Mounjaro and Zepbound have faced intermittent shortages, particularly at the 10 mg and 15 mg dose levels, through early 2025.

Prescriber Willingness

Not all primary care physicians are comfortable initiating GLP-1 agonists for obesity. A 2023 survey published in Obesity found that only 38% of PCPs had prescribed a GLP-1 for weight management in the prior year 4. Telehealth platforms have partially closed this gap, though they introduce their own cost (consultation fees, platform markups).

Geographic Variation

State-level insurance mandates affect coverage. Some states require commercial plans to cover FDA-approved anti-obesity medications. Others allow blanket exclusions. Patients in states without coverage mandates face higher denial rates and fewer appeal options.

Switching Between Wegovy and Mounjaro

Switching from one agent to the other is clinically feasible but creates access complications. Most insurance plans require a new prior authorization when switching, which can take 2-4 weeks. Some plans impose step therapy requiring documented failure on the first agent before approving the second, measured by inadequate weight loss (often defined as less than 5% at 12-16 weeks) or intolerable side effects.

Clinical Considerations When Switching

Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has noted: "Patients who plateau on one GLP-1 agonist may benefit from the dual-incretin mechanism of tirzepatide, but the insurance navigation can delay treatment by weeks."

Dose mapping is not straightforward. A patient on Wegovy 2.4 mg does not simply start Mounjaro at an equivalent dose. Tirzepatide requires its own titration from 2.5 mg, though some clinicians start at 5 mg for patients already tolerating a GLP-1 agonist. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend individualized dose titration regardless of prior GLP-1 exposure 5.

Compounded Alternatives and Their Risks

The cost barrier has driven significant patient interest in compounded semaglutide and tirzepatide from 503A and 503B pharmacies. During declared shortages, FDA enforcement discretion allowed compounding of these molecules. As shortages resolve, the regulatory status of compounded versions becomes uncertain.

Price of Compounded Versions

Compounded semaglutide has been available at $150-$400/month through telehealth platforms, roughly 70-85% below brand-name pricing. Compounded tirzepatide runs $200-$500/month at similar discounts. These prices include the compounding fee and typically a telehealth consultation.

Safety and Efficacy Concerns

The FDA issued multiple warnings in 2024-2025 regarding compounded GLP-1 products, citing sterility failures, dosing inaccuracies, and use of salt forms (semaglutide sodium) not proven bioequivalent to the branded product 6. Patients opting for compounded versions accept unknown risk profiles compared to the standardized manufacturing of Wegovy and Mounjaro.

Decision Framework: Which Is More Accessible for You?

The "better" option from a cost-access standpoint depends on individual circumstances. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends choosing agents based on efficacy, tolerability, and "practical considerations including cost and insurance coverage" 7.

Choose Wegovy if:

Your insurance explicitly covers anti-obesity medications and your primary goal is weight loss without a T2D diagnosis. The FDA obesity indication simplifies prior authorization documentation. The SELECT trial cardiovascular data may also support coverage under cardiovascular risk reduction for patients with established atherosclerotic disease 3.

Choose Mounjaro if:

You have type 2 diabetes and your plan covers Mounjaro on formulary. The dual GIP/GLP-1 mechanism produced numerically superior weight loss in SURMOUNT-1 compared to semaglutide 2.4 mg in STEP-1. If your insurer covers Zepbound for obesity, the higher efficacy ceiling may offer better value per dollar spent.

Neither Is Affordable Without Coverage

At list price, both drugs cost $12,000-$16,000 per year. Long-term adherence data suggest most patients regain weight after discontinuation, making this an ongoing rather than time-limited expense. Budget planning must account for indefinite use.

Patients facing cost barriers should request a benefits investigation through their prescriber's office, apply for manufacturer patient assistance programs, and explore state pharmaceutical assistance programs where available. Appeal denied prior authorizations with clinical documentation including BMI trajectory, comorbidity burden, and prior failed interventions.